Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis

JCI Insight

Volumn 1, Issue 5, 2016, Pages

  Jones, Mark G ^a,b   Fabre, Aurélie ^c   Schneider, Philipp ^d   Cinetto, Francesco ^e   Sgalla, Giacomo ^a,b   Mavrogordato, Mark ^d   Jogai, Sanjay ^b   Alzetani, Aiman ^b   Marshall, Ben G ^b   O’Reilly, Katherine M A ^f,g   Warner, Jane A ^a   Lackie, Peter M ^a   Davies, Donna E ^a,b,d   Hansell, David M ^h   Nicholson, Andrew G ^h   Sinclair, Ian ^d   Brown, Kevin K ⁱ   Richeldi, Luca ^a,b,d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e UNIVERSITY OF PADOVA   (Italy)

^f MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^g UNIVERSITY COLLEGE DUBLIN   (Ireland)

^h ROYAL BROMPTON HOSPITAL   (United Kingdom)

ⁱ DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85089912056     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/JCI.INSIGHT.86375     Document Type: Article

References (39)

1. Raghu G, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
2. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008;3(1):8.
3. Noble PW, Barkauskas CE, Jiang D. Pulmonary fibrosis: patterns and perpetrators. J Clin Invest. 2012;122(8):2756–2762.
4. King TE Jr, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092.
5. Richeldi L, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
6. King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949–1961.
7. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157(4):1301–1315.
8. King TE Jr, et al. Idiopathic pulmonary fibrosis — relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 2001;164(6):1025–1032.
9. Nicholson AG, et al. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2002;166(2):173–177.
10. Harada T, Watanabe K, Nabeshima K, Hamasaki M, Iwasaki H. Prognostic significance of fibroblastic foci in usual interstitial pneumonia and non-specific interstitial pneumonia. Respirology. 2013;18(2):278–283.
11. Flaherty KR, et al. Fibroblastic foci in usual interstitial pneumonia. Am J Respir Crit Care Med. 2003;167(10):1410–1415.
12. Hanak V, et al. Profusion of fibroblast foci in patients with idiopathic pulmonary fibrosis does not predict outcome. Respir Med. 2008;102(6):852–856.
13. Cool CD, et al. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med. 2006;174(6):654–658.
14. Paulus MJ, Gleason SS, Kennel SJ, Hunsicker PR, Johnson DK. High resolution X-ray computed tomography: An emerging tool for small animal cancer research. Neoplasia. 2000;2(1-2):62–70.
15. Metscher BD. MicroCT for developmental biology: a versatile tool for high-contrast 3D imaging at histological resolutions. Dev Dyn. 2009;238(3):632–640.
16. McDonough JE, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365(17):1567–1575.
17. Verleden SE, et al. The site and nature of airway obstruction after lung transplantation. Am J Respir Crit Care Med. 2014;189(3):292–300.
18. Scotton CJ, et al. Ex vivo micro-computed tomography analysis of bleomycin-induced lung fibrosis for preclinical drug evaluation. Eur Resp J. 2013;42(6):1633–1645.
19. Ask K, et al. Comparison between conventional and “clinical” assessment of experimental lung fibrosis. J Transl Med. 2008;6(1):16.
20. Rodt T, et al. Micro-computed tomography of pulmonary fibrosis in mice induced by adenoviral gene transfer of biologically active transforming growth factor-b1. Respir Res. 2010;11(1):181.
21. Cavanaugh D, et al. Quantification of bleomycin-induced murine lung damage in vivo with micro-computed tomography. Acad Radiol. 2006;13(12):1505–1512.
22. De Langhe E, et al. Quantification of lung fibrosis and emphysema in mice using automated micro-computed tomography. PLoS One. 2012;7(8):e43123.
23. Shofer S, Badea C, Auerbach S, Schwartz DA, Johnson GA. A micro-computed tomography-based method for the measurement of pulmonary compliance in healthy and bleomycin-exposed mice. Exp Lung Res. 2007;33(3–4):169–183.
24. Scott AE, et al. Three dimensional imaging of paraffin embedded human lung tissue samples by micro-computed tomography. PLoS One. 2015;10(6):e0126230.
25. Coxson HO, et al. Quantification of idiopathic pulmonary fibrosis using computed tomography and histology. Am J Respir Crit Care Med. 1997;155(5):1649–1656.
26. Ochs M, et al. The number of alveoli in the human lung. Am J Respir Crit Care Med. 2004;169(1):120–124.
27. Gundersen HJ, et al. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS. 1988;96(10):857–881.
28. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Resp J. 2010;35(3):496–504.
29. Leslie KO. Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis. Arch Pathol Lab Med. 2012;136(6):591–600.
30. Katzenstein AL, Myers JL, Prophet WD, Corley LS, Shin MS. Bronchiolitis obliterans and usual interstitial pneumonia. A comparative clinicopathologic study. Am J Surg Pathol. 1986;10(6):373–381.
31. Conte E, et al. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13–19.
32. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999;289(1):211–218.
33. Rangarajan S, et al. Novel mechanisms for the anti-fibrotic action of nintedanib. Am J Respir Cell Mol Biol. 2016;54(1):51–59.
34. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Anti-fibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor, nintedanib, in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014;349(2):209–220.
35. Feldkamp LA, Davis LC, Kress JW. Practical cone-beam algorithm. J Opt Soc Am A Opt Image Sci Vis. 1984;1(6):612–619.
36. Russell HK. A modification of Movat’s pentachrome stain. Arch Pathol Lab Me. 1972;94(2):187–191.
37. Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. Nat Meth. 2012;9(7):676–682.
38. Saalfeld S, Cardona A, Hartenstein V, Tomancak P. As-rigid-as-possible mosaicking and serial section registration of large ssTEM datasets. Bioinformatics. 2010;26(12):i57–i63.
39. Nyengaard JR, Marcussen N. The number of glomerular capillaries estimated by an unbiased and efficient stereological method. J Microsc. 1993;171(pt 1):27–37.